摘要
目的:观察戈舍瑞林联合米非司酮治疗子宫肌瘤疗效及对患者血清性激素、转化生长因子β1(TGF-β1)、肿瘤特异性生长因子(TSGF)和子宫内膜影响。方法:纳入2022年5月-2023年10月于本院收治的子宫肌瘤患者160例并随机分为对照组和观察组各80例,两组均给予米非司酮治疗,观察组联合给予戈舍瑞林治疗,均连续给药6个月。比较两组临床疗效,治疗前后性激素、TGF-β1、TSGF和子宫内膜厚度。结果:观察组总有效率(91.3%)高于对照组(80.0%),孕酮(3.12±1.05μmol/L)、睾酮(0.89±0.27μmol/L)、泌乳素(12.01±3.41μg/L)、TGF-β1(10.98±2.59 ng/L)、TSGF(27.86±7.84μmol/L)、子宫体积(176.42±94.51 cm^(3))、肌瘤体积(28.09±9.51 cm^(3))和子宫内膜厚度(0.87±0.05 cm)均低于对照组(4.67±1.87μmol/L、1.96±0.89μmol/L、15.42±3.98μg/L、12.43±2.76 ng/L、34.72±9.85μmol/L、209.88±98.75 cm^(3)、32.43±9.84 cm^(3)、0.94±0.09 cm)(均P<0.05);治疗不良反应观察组(18.8%)与对照组(15.0%)无差异(P>0.05)。结论:米非司酮治疗子宫肌瘤均有效,戈舍瑞林联合米非司酮治疗效果更佳,可更好地调节患者性激素,降低TGF-β1、TSGF水平,减小子宫体积、肌瘤体积和子宫内膜厚度,未增加不良反应。
Objective:To investigate the efficacy of goserelin combined with mifepristone for treating patients with uterine fibroids,and to study its influence on the levels of serum sex hormones,transforming growth factorβ1(TGF-β1)and tumor specific growth factor(TSGF)of the patients.Methods:A total of 160 patients with uterine fibroids admitted to hospital were collected and randomly divided into two groups from May 2022 to October 2023.80 patients in the control group received treatment of mifepristone for 6 months continuously,and 80 patients in the observation group received treatment of goserelin combined with mifepristone for 6 months continuously.The clinical therapeutic effect and the levels of sex hormones,TGF-β1 and TSGF,and the endometrial thickness of the patients before and after treatment were compared between the two groups.Results:The total effective rate(91.3%)of the patients in the observation group was significantly higher than that(80.0%)of the patients in the control group.The levels of progesterone(3.12±1.05μmol/L),testosterone(0.89±0.27μmol/L),prolactin(12.01±3.41μg/L),TGF-β1(10.98±2.59 ng/L)and TSGF(27.86±7.84μmol/L),and the values of uterine volume(176.42±94.51 cm^(3)),fibroid volume(28.09±9.51 cm^(3))and endometrial thickness(0.87±0.05 cm)of the patients in the observation group were significantly lower than those(4.67±1.87μmol/L,1.96±0.89μmol/L,15.42±3.98μg/L,12.43±2.76 ng/L,34.72±9.85μmol/L,209.88±98.75 cm^(3),32.43±9.84 cm^(3) and 0.94±0.09 cm)of the patients in the control group(all P<0.05).There was no significant difference in the adverse reactions rate(18.8%vs.15.0%)of the patients between the two groups(P>0.05).Conclusion:Both mifepristone and goserelin has the effect for treating the patients with uterine fibroids,but goserelin combined with mifepristone has better effect,and which can regulate the sex hormones levels,reduce the TGF-β1 and TSGF levels,and decrease the uterus volume,fibroid volume and endometrial thickness of the patients,and without increasing the adverse reactions.
作者
于迎春
计春敏
李荣
杨秀兰
YU Yingchun;JI Chunmin;LI Rong;YANG Xiulan(The Air Force Hospital of Eastern Theater of PLA,Nanjing,Jiangsu Province,210002;The Second Affiliated Hospital of Air Force Medical University(Tangdu Hospital),Xian,Shanxi Province;Nanjing Yuhuatai District Yuhua Community Health Service Center,Nanjing,Jiangsu Province)
出处
《中国计划生育学杂志》
2024年第6期1295-1299,共5页
Chinese Journal of Family Planning
